Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Comparing extremes of the spectrum, multivariable analyses generally showed significantly higher risks for patients with high ...

A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...

Every Australian adult should be screened for a potentially deadly type of inherited cholesterol, and if the simple blood ...

Lipoprotein(a), a fatty particle, can clog arteries just as surely as cholesterol but often goes undetected, striking ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

All sex, race, and risk category groups appeared to be affected by the heart disease risk posed by elevated lipoprotein(a), or Lp(a), according to pooled analysis of primary prevention studies.